Zobrazeno 1 - 10
of 12
pro vyhledávání: '"J Playan Escribano"'
Autor:
J Playan Escribano, E Garrido-Lestache, R Luna, M Alvarez Fuente, M Lopez-Meseguer, I Guillen Rodriguez, G M Perez Penate, A Sabate Rotes, T Elias Hernandez, M Lopez Ramon, J Rueda Soriano, F Perin, I Blanco, M J Del Cerro Marin, P Escribano Subias
Publikováno v:
European Heart Journal. 43
Pulmonary arterial hypertension (PAH) is a common complication of congenital heart disease (CHD) that significantly affects its prognosis. Down syndrome is a common comorbidity among patients with PAH associated with CHD. Children born in recent year
Autor:
J Playan Escribano, E Garrido-Lestache, M J Cristo Ropero, M Alvarez Fuente, J A Barbera, A Moreno Galdo, J Rueda Soriano, A Rodriguez Ogando, T Elias Hernandez, I Guillen Rodriguez, M Lazaro Salvador, M Lozano Balseiro, A Lara Padron, P Escribano Subias, M J Del Cerro Marin
Publikováno v:
European Heart Journal. 42
Introduction Eisenmenger syndrome is the final clinical stage of different congenital heart diseases (CHD) associated with pulmonary arterial hypertension (PAH). Children born in recent years with CHD have benefited from advances in pediatric cardiac
Autor:
A Cruz Utrilla, N Gallego, A Torrent, E Garrido-Lestache, I Guillen, S Arias, A Moya, A Mendoza, J Espin, M M Rodriguez Vazquez, J Playan-Escribano, C Labrandero, J A Tenorio Castano, P Escribano Subias, M J Del Cerro
Publikováno v:
European Heart Journal. 42
Background Pulmonary arterial hypertension (PAH) is a rare and severe disease, genetically predisposed in a high proportion of patients. PAH is subclassified in different subtypes depending on the underlying condition. Gene variants are more frequent
Autor:
J C Gomez Polo, Antonio Tello-Montoliu, J Playan Escribano, Inmaculada Roldán, D. Vivas Balcones, I Silva, A Besteiro Vazquez, José Luis Ferreiro, Joan-Antoni Gomez-Hospital, Esther Bernardo, M.A Ortega, A.L Marcano Fernandez, L.M Lugo Gavidia, J.M De La Hera Galarza, Francisco Marcos Marín
Publikováno v:
European Heart Journal. 41
Background Different “ex vivo” studies have shown both a greater platelet activation and higher rates of resistance to clopidogrel in obese patients. Although there is less evidence, less prasugrel activity has also been observed in these patient
Autor:
M Zapata Sanchez, A. Moreno Galdó, T Segura De La Cal, J Playan Escribano, M.T Viadero Ubierna, B Plata Izquierdo, E Gomez Guzman, A. Rodriguez Ogando, C Labrandero, J.M Espin Lopez, M.J. del Cerro Marín, F Perin, A. Moya Bonora, M Lozano Balseiro, P Escribano Subias, Rehiped investigators
Publikováno v:
European Heart Journal. 41
Background Pulmonary arterial hypertension (PAH) includes idiopathic PAH and congenital heart disease (CHD) related PAH. A wide variety of CHD can develop PAH, but their clinical characteristics define four large groups: Eisenmenger, PAH associated w
Autor:
M Lopez Ramon, M.J. del Cerro Marín, S Villagra Albert, G Inigo Martin, L M Caicedo Cuenca, T Segura De La Cal, A Sabate Rotes, I Guillen Rodriguez, C Labrandero, J Playan Escribano, L Conejo Munoz, S. Escriba Bori, P Escribano Subias, M.A Izquierdo Riezu, A Mendoza Soto
Publikováno v:
European Heart Journal. 41
Introduction Pulmonary arterial hypertension (PAH) is a rare disease that affects the small pulmonary arteries, producing gradual obliteration of arterial lumen leading to the progressive increase in pulmonary vascular resistance and, ultimately, rig
Autor:
M Lopez Ramon, L Molina Ferragut, J.A. Barberà Mir, M Lazaro Salvador, J Playan Escribano, R Lopez Reyes, L Dos Subira, E Martinez-Quintana, Suberviola, I. Otero González, A Martinez Menaca, Rehap investigators Rehiped investigators, E Barrios Garrido-Lestache, Elvira Barrios Garrido-Lestache, P Escribano Subias, T Segura De La Cal
Publikováno v:
European Heart Journal. 41
Introduction Pulmonary arterial hypertension (PAH) is a common comorbidity in congenital heart disease (CHD) and significantly affects prognosis. Our aim was to investigate how the location of the shunt influences the outcome of these patients. Metho
Autor:
J.C Gomez Polo, D Vivas Balcones, A.L Marcano Fernandez, J Playan Escribano, L.M Lugo Gavidia, E Bernardo, M.A Ortega Pozzi, J.M De La Hera Galarza, A Tello Montoliu, A Besteiro Vazquez, I Silva, F Marin, I Roldan Rabadan, J.A Gomez Hospital, J.L Ferreiro
Publikováno v:
European Heart Journal. 41
Background Several pharmacodynamic studies have shown the impact of smoking habit on platelet reactivity; with a reduction on platelet aggregation. Wether this inhibition in platelet reactivity is due to tobacco effects in platelet signaling pathways
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.